Currently, there have been five registered active clinical trials investigating the targeting of BET family proteins, such as RVX-208, I-BET 762, OTX 015, CPI-0610 and TEN-010, which reported encouraging results in treating hematologic malignancies (https://clinicaltrials.gov/). The gene discussed is DNER; the disease is hematologic disorder.